Back to Trials
NCT03297775Recruiting

Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease

University of Colorado, Denver

Start Date

6/22/2017

Completion Date

6/1/2027

Summary

The overall goal of this study is to define the phenotype of Interstitial Lung Disease (ILD), and identify factors that predict radiologic progression in those with subclinical RA-ILD, in patients with rheumatoid arthritis (RA). The investigators hypothesize that there are common core elements (e.g. clinical features, genetic variants, and/or biologic markers) between other forms of ILD (e.g. idiopathic pulmonary fibrosis, IPF) and subclinical RA-ILD that places individuals at risk for the development of lung disease.

Eligibility Criteria

Age Range: 45 years to 90 years

Inclusion Criteria: 1. ≥ 45years old 2. Diagnosis of RA using the 2010 American College of Rheumatology (ACR) criteria Exclusion Criteria: 1. Inability to give informed consent 2. Pregnant women 3. History of interstitial lung disease 4. Evidence of other causes of diffuse parenchymal lung disease such as infection, drug toxicity, other autoimmune processes, etc. 5. Subjects over the age of 90 years old or less than 45 years old

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Rheumatoid ArthritisInterstitial Lung Disease

Locations

University of Colorado - Anschutz Medical Campus

Aurora, Colorado 80045

United States